Startup profile for Tesorai: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Tesorai funding, valuation and investors

Cloud proteomics platform that reprocesses raw mass-spectrometry data and compares results with curated research datasets.

Verified company research · funding, investors and latest developments

Keep track of Tesorai

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$5.3M · November 18, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$5.3M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

seed · San Diego, California, USA

Investors in latest funding

Other: Perplexity Fund , IQT , South Central Ventures , New Stack Ventures , NextGen Venture Partners , f7 Ventures , VitalStage Ventures , ZAKA

Sources: latest funding · prnewswire.com Last verified: 2026-11-19

Overview

San Diego-based Tesorai was founded by Melissa Miao, Peter Cimermancic and Charlie Kim, former Google/Verily colleagues. It provides Tesorai Search for data-dependent and data-independent mass-spectrometry searches, Tesorai Chat for quality control and downstream analyses, and Trove for curated public proteomics datasets. The firm says it has biopharma/research contracts and collaborations with named institutions.

Prices for commercial licenses, revenue, retention and valuation are not disclosed; free platform access does not establish commercial pricing.

Why Tesorai is interesting

Its $5.3M November 18 seed brings funding to $8M; researchers can revisit raw experiments rather than rely only on published paper conclusions. A claimed Alzheimer's biomarker rediscovery is a preprint finding, not a diagnostic validation.

Product & use cases

Documented research workflow: (1) upload raw DDA/DIA mass-spectrometry files to Tesorai Search; (2) select reference database, modifications and search parameters; (3) process spectra to peptide/protein assignments; (4) use Chat to inspect QC/statistics and export results; (5) use Trove to retrieve and analyze comparable curated public studies to test whether a protein signal repeats. Users are bioinformaticians, pharma discovery teams and research labs. Tesorai handles raw data rather than replacing wet-lab experimentation or establishing a medical diagnosis.

  • Reanalyze historical raw proteomics experiments with current identification models.
  • Cross-validate protein biomarkers across distinct public brain or tissue studies.
  • Prepare harmonized experimental feature data for biological AI training.

Key facts

  • $5.3M seed announced November 18, 2026; cumulative $8M, investors named but no issuer-confirmed lead.
  • Search / Trove / Chat support mass-spectrometry reanalysis and cross-study replication.
  • The reported p-tau217 rediscovery derives from an August company preprint; independent biomarker validation remains necessary.

Funding history (newest first)

Seed

2026-11-18 $5.3M
  • Perplexity Fund (participant)
  • IQT (participant)
  • South Central Ventures (participant)
  • New Stack Ventures (participant)
  • NextGen Venture Partners (participant)
  • f7 Ventures (participant)
  • VitalStage Ventures (participant)
  • ZAKA (participant)

Source: Read source · prnewswire.com

Competitive landscape

Edge: Reprocessing raw spectra plus cross-study comparison may expose signals lost in older analysis pipelines. Proprietary model performance and claimed speedups require reproducible independent benchmarking.

Unlike literature search services, Tesorai describes raw-file reprocessing and cross-study comparison. Case studies are vendor-reported and may not generalize across instruments or sample types. Trial access is advertised, but subscription pricing remains unknown.

  • MaxQuant alternative

    Established open-source proteomics analysis pipelines; typically more hands-on compute operations.

  • FragPipe alternative

    Free modular mass-spectrometry processing ecosystem; compare statistical validation and portability.

  • DIA-NN alternative

    Specialized DIA mass-spec identification and quantitation.

  • Proteome Discoverer incumbent

    Commercial proteomics processing software with strong instrument ecosystem.

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.